Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $15.8 million, down $2.4 million or 13% year-over-year, primarily due to a mid-teens decline in systems revenue and a mid-single-digit decline in procedure-related products and service revenue [6][24] - Lease revenue declined by $3.5 million or 58% year-over-year in Q4, offsetting mid-teens growth in cash system sales [7][24] - Cash system sales in the U.S. increased 27% year-over-year, representing 87% of total U.S. system sales in Q4 compared to 58% last year [8][10] - Gross profit decreased by $1.2 million or 10% to $10.9 million, with gross margin improving to 69.1% from 66.5% year-over-year [29] Business Line Data and Key Metrics Changes - Systems revenue from internal lease programs decreased to approximately 20% in Q4 2024 from 41% in the prior year, reflecting a strategic shift towards cash sales [25] - Cash systems revenue and sales of products and services increased by 10% year-over-year in Q4 [24][25] - The company achieved a 14% reduction in cash used in operations year-over-year in 2024, indicating progress in operational efficiency [15] Market Data and Key Metrics Changes - The decline in global systems adoption was attributed to macroeconomic headwinds, including customer financing pressures and economic uncertainty [9][10] - Sales through distributors more than doubled year-over-year in Q4, particularly in the APAC and EMEA regions [12] Company Strategy and Development Direction - The company is focused on transitioning to higher quality cash revenues and has made significant progress in restructuring its debt obligations, reducing total debt from $74.9 million to approximately $39.7 million [17][20] - The strategic initiatives include cost reductions, shifting to cash sales, and working capital management, which are expected to enhance long-term profitability [14][15] - The company plans to launch a new body device in the second half of 2025, which is anticipated to drive growth [54] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that while the strategic transition is largely complete, macroeconomic challenges will continue to impact quarterly performance [14][36] - The company is not providing full-year 2025 financial guidance but expects total revenue for Q1 2025 to be at least $14 million [36] Other Important Information - A 1 for 11 reverse stock split was announced, with the company's common stock trading on an adjusted basis starting March 4, 2025 [21] - The company secured an amendment to its bridge loan agreement, increasing financing capacity by $10 million [22][34] Q&A Session Summary Question: Can you characterize the expected normalized business profile going forward? - Management indicated that while predicting the macroeconomic environment is challenging, they expect performance to improve compared to 2024, with less decline anticipated [40][42] Question: How is the Venus Hair business performing? - Management expressed satisfaction with the performance of the Venus Hair business, particularly the Venus ARTAS Robot, and noted ongoing R&D innovations [44][46] Question: What is the strategy for top-line growth in 2025? - The focus will be on establishing a normal rhythm of orders with new distribution partners internationally and launching a new body system in the U.S. [52][54] Question: Are there further cost-cutting measures available? - Management stated that the infrastructure is efficient, and the focus is on increasing sales rather than further cost reductions [56][58] Question: How do tariffs affect the business? - Products are manufactured in both the U.S. and Israel, with no substantial near-term impact expected from tariffs at this time [60]

Financial Data and Key Metrics Changes - For Q4 2024, total revenue was $702.8 million, flat compared to Q4 2023, while full year revenue reached $2.79 billion, a slight increase of just over 1% [61][63] - Adjusted EBITDA for Q4 was $40.4 million, totaling $161.1 million for the full year, reflecting a decrease of approximately 20% [11][62] - Consolidated net loss for Q4 was $23.5 million, while adjusted net income was $2.7 million, or $0.19 per share [63] Business Line Data and Key Metrics Changes - The NEMT segment, representing 70% of total revenue, generated $495 million in revenue, remaining flat year over year [64] - Personal Care Services (PCS) revenue increased by 3% year over year to $186.6 million, driven by a 3.5% growth in revenue per hour [68] - Remote Patient Monitoring (RPM) revenue was $19.2 million, representing 3% of total revenue but 16% of adjusted EBITDA [69] Market Data and Key Metrics Changes - Average monthly members in the NEMT segment decreased by approximately 11% year over year, while trip volume increased by 8.5% compared to a year ago [64] - The total addressable market for NEMT is estimated to exceed $6 billion, with an annual MCO revenue base of $1 billion entering 2025 [31] Company Strategy and Development Direction - The company aims to strengthen technology-enabled platforms across NEMT, personal care, and monitoring while executing strategic financial initiatives and divesting platforms [12][22] - A focus on monetizing select segments and unlocking value is emphasized, with a strategic alternatives committee established to oversee the divestiture process [22][23] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the unprecedented challenges faced in 2024, including Medicaid redetermination and increased healthcare utilization, but expressed confidence in navigating these disruptions [8][9] - The company is optimistic about future growth opportunities, particularly in the MCO segment, with a win rate exceeding 90% over the past two years [31] Other Important Information - The company secured an incremental $75 million term loan and $30 million in new second lien notes to enhance financial flexibility [14][60] - New board appointments were made to enhance expertise in operational efficiency and technology innovation [15][20] Q&A Session Summary Question: How does ModivCare Inc.'s exposure to Medicaid affect fee-for-service contracts? - Management expects that any Medicaid cuts will primarily affect healthier members, and they are currently negotiating to reset payments based on member mix [78][80] Question: Can you provide an update on the sale process? - Management indicated that discussions are ongoing and they are encouraged by the interest in their platforms, but specific timing for sales was not disclosed [83][84] Question: What is the current membership status in NEMT and monitoring? - Membership in NEMT has decreased significantly, with expectations of recovery as new contracts are pursued [89][90] Question: What are the expectations for cash flow in 2025? - Management confirmed that they expect a return to positive free cash flow in the latter half of 2025, with improvements in contract structures aiding liquidity [112][117] Question: How will the transition from shared risk to fee-for-service contracts impact revenue? - Approximately 25% of revenue is expected to shift to fee-for-service contracts, which will help stabilize cash flow and reduce working capital shifts [124][126]